Strigini retiring as Novartis Oncology's CEO

Novartis AG (NYSE:NVS; SIX:NOVN) said Bruno Strigini will retire as CEO of Novartis Oncology by early 2018. He will leave the company's executive committee by Dec. 31. Spokesperson Eric Althoff told BioCentury that Novartis is conducting an internal and external search for Strigini's replacement.

Novartis hired Strigini as president of oncology in 2014. He became CEO of Novartis Oncology in 2016 after the company split its pharmaceutical unit into Novartis Pharmaceuticals and Novartis Oncology (see BioCentury, May 23, 2016)...